Critical Path Public Private Partnerships Clinical Trials Optional

The FDA is seeking to renew its cooperative agreement with the Critical Path Institute to sustain and expand existing public-private consortia established under the Critical Path Initiative, as authorized by Section 566 of the Federal Food, Drug, and Cosmetic Act. This effort supports the development of innovative collaborative projects aimed at accelerating drug product innovation, improving the efficiency of development and manufacturing processes, and enhancing the safety, efficacy, quality, and performance of therapeutics through research, education, and outreach. The renewal includes continued management of consortia groups already in place and is contingent upon the availability of FDA funding. The initiative aligns with broader goals to modernize regulatory science and foster partnerships across industry, academia, and government to advance medical product development. The opportunity is publicly forecasted under the title “Critical Path Public Private Partnerships Clinical Trials Optional,” with the posting date recorded as November 30, 2023. Point of contact for inquiries is Terrin Brown, Grantor at the FDA, reachable via email or phone. The funding opportunity falls under the Department of Health and Human Services and is administered by the Food and Drug Administration, though no specific set-aside, NAICS code, or place of performance details are provided. The application process is open to entities interested in continuing critical collaborative work under the existing framework, with no indication of geographic restrictions or eligibility limitations beyond alignment with the initiative’s objectives.